L’Oréal Group has signed an agreement to acquire a majority stake in UK-based skincare brand Medik8.
Inflexion, a European mid-market private equity company, will retain a minority share post-transaction.
The acquisition is a strategic move by L’Oréal to bolster its Luxe division with a brand that has a strong foundation in scientific research and innovation.
Medik8’s performance and potential for international expansion make it a valuable addition to L’Oréal’s portfolio.
L’Oréal will begin to consolidate Medik8’s sales following the transaction’s closure. The agreement grants L’Oréal rights to eventually acquire the remaining shares held by minority shareholders.
L’Oréal LUXE president Cyril Chapuy stated: “We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We share a strong belief in Medik8’s global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”
Completion of the transaction is anticipated in the summer or early autumn of 2025, pending regulatory approvals.
Founded by scientist Elliot Isaacs, Medik8 is known for its CSA Philosophy: Vitamin C plus Sunscreen by day, Vitamin A by night.
Medik8’s has expanded its omni-channel sales strategy to include major online and offline retailers in Europe and the US.
Medik8 CEO Simon Coble stated: “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”
